EyePoint Pharmaceuticals Inc (EYPT)
10.71
-0.04
(-0.37%)
USD |
NASDAQ |
May 31, 16:00
10.70
-0.01
(-0.09%)
After-Hours: 20:00
EyePoint Pharmaceuticals Research and Development Expense (Quarterly): 30.14M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 30.14M |
| December 31, 2023 | 17.95M |
| September 30, 2023 | 17.36M |
| June 30, 2023 | 15.73M |
| March 31, 2023 | 13.62M |
| December 31, 2022 | 15.54M |
| September 30, 2022 | 11.16M |
| June 30, 2022 | 12.99M |
| March 31, 2022 | 9.945M |
| December 31, 2021 | 8.918M |
| September 30, 2021 | 8.498M |
| June 30, 2021 | 5.605M |
| March 31, 2021 | 5.479M |
| December 31, 2020 | 5.205M |
| September 30, 2020 | 4.09M |
| June 30, 2020 | 3.276M |
| March 31, 2020 | 4.853M |
| December 31, 2019 | 4.131M |
| September 30, 2019 | 3.484M |
| June 30, 2019 | 3.955M |
| March 31, 2019 | 3.797M |
| September 30, 2018 | 6.233M |
| June 30, 2018 | 4.765M |
| March 31, 2018 | 3.325M |
| December 31, 2017 | 4.269M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.819M |
| June 30, 2017 | 4.213M |
| March 31, 2017 | 3.324M |
| December 31, 2016 | 3.165M |
| September 30, 2016 | 4.178M |
| June 30, 2016 | 4.104M |
| March 31, 2016 | 3.074M |
| December 31, 2015 | 3.721M |
| September 30, 2015 | 3.482M |
| June 30, 2015 | 3.198M |
| March 31, 2015 | 3.339M |
| December 31, 2014 | 2.767M |
| September 30, 2014 | 2.784M |
| June 30, 2014 | 2.306M |
| March 31, 2014 | 2.269M |
| December 31, 2013 | 2.494M |
| September 30, 2013 | 2.504M |
| June 30, 2013 | 2.32M |
| March 31, 2013 | 1.587M |
| December 31, 2012 | 1.575M |
| September 30, 2012 | 1.523M |
| June 30, 2012 | 1.41M |
| March 31, 2012 | 1.508M |
| December 31, 2011 | 1.992M |
| September 30, 2011 | 2.129M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.276M
Minimum
Jun 2020
30.14M
Maximum
Mar 2024
10.10M
Average
8.708M
Median
Research and Development Expense (Quarterly) Benchmarks
| Nanoviricides Inc | 1.215M |
| Bio-Path Holdings Inc | 2.288M |
| GlycoMimetics Inc | 6.026M |
| Ocular Therapeutix Inc | 20.74M |
| Aileron Therapeutics Inc | 3.463M |